ReviewResearch and practice in thrombosis and haemostasis2026
The therapeutic landscape of inherited bleeding disorders in China.
Review in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The demand for diagnosis and treatment of inherited bleeding disorders, particularly hemophilia, is increasing in China. In recent years, significant progress has been made in the country regarding the development and application of related therapeutics and the construction of the Chinese healthcare delivery system with attention to more efficient, cost-effective and convenient healthcare access to the population in both the remote/rural and urban areas. This article aims to systematically review the current therapeutic landscape of inherited bleeding disorders in China, elucidate the developmental pipeline of investigational domestic novel drugs, and discuss the establishment of a tiered healthcare system for hemophilia in China in line with the developing national healthcare delivery system. Attention to research and development in China have resulted in increased therapeutic product manufacturing capacity, and China is progressively establishing a domestic supply system for therapeutics ranging from basic replacement therapies to advanced treatments including gene therapy for inherited bleeding disorders. Concurrently, the ongoing development of the tiered healthcare system is expected to optimize the allocation of medical resources and enhance the standardization of diagnosis and treatment nationwide. In the future, the successful development of domestic innovative drugs, combined with an efficient and cost-effective healthcare delivery system, will lay a solid foundation for improving treatment outcomes and the quality of life for patients in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.